Ciluprevir
![]() | |
Systematic (IUPAC) name | |
---|---|
(1S,4R,6S,7Z,14S,18R)-14- {[(cyclopentyloxy)carbonyl]amino}-18-[(7-methoxy-2- {2-[(propan-2-yl)amino]-1,3-thiazol-4-yl}quinolin-4- yl)oxy]-2,15-dioxo-3,16- diazatricyclo[14.3.0.0{4,6}]nonadec-7-ene-4- carboxylic acid | |
Clinical data | |
| |
Identifiers | |
300832-84-2 | |
None | |
PubChem | CID 9853710 |
ChemSpider | 8029420 |
UNII |
75C8DU40T0 ![]() |
ChEMBL | CHEMBL297884 |
Chemical data | |
Formula | C40H50N6O8S |
774.93 g/mol | |
SMILES
| |
|
Ciluprevir is used experimentally in the treatment of hepatitis C. It is manufactured by Boehringer Ingelheim Pharma GmbH & Co. kg and developed under the research code of BILN-2061. It is targeted against NS2-3 protease.[1]
References
- ↑ Abbenante, G; Fairlie, DP (2005). "Protease inhibitors in the clinic". Medicinal chemistry 1 (1): 71–104. doi:10.2174/1573406053402569. PMID 16789888.